Evidence map›Paper›PMID 42184296›Full record

ReviewSingapore medical journal2026

Positioning of advanced therapies in patients with moderate-to-severe Crohn's disease.

Tian Yu Qiu, Chin Kimg Tan, Jeannie Peng Lan Ong, Khoon Lin Ling

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Singapore medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tian Yu QiuDepartment of Gastroenterology and Hepatology, Changi General Hospital, Singapore.
Chin Kimg TanDepartment of Gastroenterology and Hepatology, Changi General Hospital, Singapore.
Jeannie Peng Lan OngDepartment of Gastroenterology and Hepatology, Changi General Hospital, Singapore.
Khoon Lin LingDepartment of Gastroenterology and Hepatology, Changi General Hospital, Singapore.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractThe treatment landscape for Crohn's disease (CD) has evolved substantially in the 21st century with the advent of advanced therapies. Since the introduction of tumour necrosis factor (TNF) antagonists, new classes of advanced CD therapies have been approved for use in the Asia-Pacific region, including anti-integrins, interleukin (IL)-12/23p40 inhibitors, IL-23p19 inhibitors and Janus kinase inhibitors (JAKi). In the last 10 years, biosimilars to infliximab, adalimumab and ustekinumab and generic JAKi have also become available. In this review, we discuss the indications for advanced therapies and whether certain classes of drugs are preferred for specific patient subsets. We also discuss the choice of first- and second-line agents for CD.

Indexed as

Crohn DiseaseAdalimumabAntibodies, MonoclonalHumansInfliximabJanus Kinase InhibitorsSeverity of Illness IndexTumor Necrosis Factor-alphaUstekinumabAdalimumabAntibodies, MonoclonalInfliximabJanus Kinase InhibitorsTumor Necrosis Factor-alphaUstekinumabAdvanced therapyCrohn’s diseaseinflammatory bowel disease

Identifiers

PMID42184296
PMCPMC13327688

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.